Patents by Inventor Kimberly Ann Marquette
Kimberly Ann Marquette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240181071Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: ApplicationFiled: October 23, 2023Publication date: June 6, 2024Applicant: Pfizer Inc.Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Publication number: 20240156977Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: ApplicationFiled: October 23, 2023Publication date: May 16, 2024Applicant: Pfizer Inc.Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Publication number: 20240117030Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Rita Diane AGOSTINELLI, James Reasoner APGAR, Eric Matthew BENNETT, Laird BLOOM, Ting CHEN, Aaron Michael D'ANTONA, Arnab DE, Fang JIN, Marion Teresa KASAIAN, Matthew Allister LAMBERT, Kimberly Ann MARQUETTE, Virginie MCMANUS, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Richard Thomas SHELDON, Lioudmila TCHISTIAKOVA, Alexander Michael Shuford BARRON, Richard Lee GIESECK, III, Xiaotian ZHONG
-
Publication number: 20240059799Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.Type: ApplicationFiled: May 9, 2023Publication date: February 22, 2024Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
-
Patent number: 11833216Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: GrantFiled: February 9, 2023Date of Patent: December 5, 2023Assignee: Pfizer Inc.Inventors: Andrea Therese Hooper, Kimberly Ann Marquette, Chakrapani Subramanyam, Hans-Peter Gerber, Chad Michael May
-
Publication number: 20230241235Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: ApplicationFiled: February 9, 2023Publication date: August 3, 2023Applicant: Pfizer Inc.Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Publication number: 20220119545Abstract: The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.Type: ApplicationFiled: November 7, 2019Publication date: April 21, 2022Inventors: Lewis C. CANTLEY, Stephen P. SOLTOFF, Brooke M. EMERLING, George POULOGIANNIS, Cindy M. HODAKOSKI, Hui LIU, Irina APOSTOLOU, Brian Gaither BATES, Kimberly Ann MARQUETTE, Eric M. BENNETT, Lidia MOSYAK, Lioudmila G. TCHISTIAKOVA, Edward Christian ROSFJORD, Isaac J. RONDON, Chao Bai HUANG
-
Publication number: 20200377615Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: June 3, 2020Publication date: December 3, 2020Applicant: Pfizer Inc.Inventors: Dangshe MA, Frank LOGANZO, Jr., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
-
Patent number: 10689458Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.Type: GrantFiled: November 21, 2016Date of Patent: June 23, 2020Assignee: Pfizer Inc.Inventors: Dangshe Ma, Frank Loganzo, Jr., Kimberly Ann Marquette, Edmund Idris Graziani, Puja Sapra, Pavel Strop
-
Publication number: 20200069764Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.Type: ApplicationFiled: November 19, 2019Publication date: March 5, 2020Applicant: Pfizer Inc.Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
-
Publication number: 20190269791Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.Type: ApplicationFiled: October 3, 2017Publication date: September 5, 2019Applicant: Pfizer Inc.Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Patent number: 10189896Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: December 16, 2017Date of Patent: January 29, 2019Assignee: PFIZER INC.Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Publication number: 20180265578Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: ApplicationFiled: December 16, 2017Publication date: September 20, 2018Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Patent number: 9850301Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: August 7, 2016Date of Patent: December 26, 2017Assignee: PFIZER INC.Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Publication number: 20170319711Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: May 23, 2016Publication date: November 9, 2017Applicant: WYETH LLCInventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova
-
Publication number: 20170216452Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.Type: ApplicationFiled: November 21, 2016Publication date: August 3, 2017Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
-
Publication number: 20170151341Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: November 21, 2016Publication date: June 1, 2017Applicant: Pfizer Inc.Inventors: Dangshe MA, Frank LOGANZO, JR., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
-
Publication number: 20170145084Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: ApplicationFiled: August 7, 2016Publication date: May 25, 2017Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Patent number: 9409981Abstract: The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: March 8, 2013Date of Patent: August 9, 2016Assignee: Pfizer Inc.Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Publication number: 20140081005Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: October 14, 2013Publication date: March 20, 2014Applicant: WYETH LLCInventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova